

Caterina Vivaldi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2063272/caterina-vivaldi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

1,016
citations

16
h-index

28
g-index

115
ext. papers

1,374
ext. citations

4.9
avg, IF

3.86
L-index

#	Paper	IF	Citations
94	Detailing the ultrastructure & increase of prion protein in pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2021 , 27, 7324-7339	5.6	0
93	Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis. <i>Targeted Oncology</i> , 2021 , 16, 401-410	5	1
92	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3665-3671	4.9	4
91	Feasibility of Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. <i>Diagnostics</i> , 2021 , 11,	3.8	2
90	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021 , 23, 915-920	3.8	4
89	Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. <i>Updates in Surgery</i> , 2021 , 73, 233-249	2.9	4
88	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021 , 10, 370-379	9.1	10
87	Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. <i>Pharmacogenomics Journal</i> , 2021 , 21, 233-242	3.5	4
86	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	4
85	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021 , 41, 1389-1397	7.9	14
84	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta Oncologica</i> , 2021 , 60, 1317-1324	3.2	2
83	In Reply. <i>Oncologist</i> , 2021 , 26, e1895-e1896	5.7	
82	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2021 , 1-10	2.3	0
81	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
80	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021 , 51, 1229-1241	5.1	2
79	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. <i>Targeted Oncology</i> , 2021 , 16, 653-661	5	
78	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 4485-4493	12.9	9

77	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020 , 15, e0232449	3.7	23
76	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020 , 147, 3177-3188	7.5	9
75	Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
74	Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2020 , 43, 1305-1314	2.7	13
73	Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. <i>Frontiers in Oncology</i> , 2020 , 10, 64	5.3	4
72	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020 , 15, 115-126	5	11
71	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. <i>Oncologist</i> , 2020 , 25, 886-893	5.7	12
70	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
69	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 773-785	5	8
68	In Reply. <i>Oncologist</i> , 2020 , 25, e1819	5.7	
67	First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. <i>European Journal of Cancer</i> , 2020 , 137, 108-116	7.5	6
66	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists 2020 , 8,		4
65	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 2020 , 15, e0232449		
64	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 2020 , 15, e0232449		
63	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 2020 , 15, e0232449		
62	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 2020 , 15, e0232449		
61	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101889	14.4	39
60	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , 2019 , 6, 92-107	1.3	19

59	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e394-e401	3.8	7
58	Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1978-1979	2.2	1
57	FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 1187-1198	11.88	7
56	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019 , 111, 94-106	7.5	25
55	Neuroendocrine Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1053-1054	2.7	
54	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019 , 110, 32-41	7.5	12
53	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. <i>British Journal of Cancer</i> , 2019 , 120, 522-526	8.7	8
52	Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. <i>Cancers</i> , 2019 , 11,	6.6	4
51	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14054-e14054	2.2	
50	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019 , 20, 49-68	2.6	18
49	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018 , 118, 820-824	8.7	117
48	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018 , 12, 33-37	4.5	2
47	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. <i>Cancer Biomarkers</i> , 2018 , 21, 731-741	3.8	7
46	Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. <i>Cancer Treatment Reviews</i> , 2018 , 69, 90-100	14.4	11
45	Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 351-351	2.2	1
44	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 210-210	2.2	
43	An easy-to-use nomogram to predict overall survival (OS) at 6 months after initiation of FOLFIRINOX first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 394-394	2.2	
42	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16119-e16119	2.2	

41	Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinix in pancreas cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24128-e24128	2.2	
40	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018 , 104, 476-479	1.7	12
39	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1272-1275	2.7	2
38	Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. <i>Cancer Treatment Reviews</i> , 2018 , 69, 11-20	14.4	24
37	Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 114, 24-32	7	13
36	Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?. <i>Annals of Oncology</i> , 2017 , 28, 667	10.3	4
35	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017 , 13, 2265-2275	3.6	8
34	Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer. <i>Translational Gastroenterology and Hepatology</i> , 2017 , 2, 11	5.2	
33	Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. <i>Scientific Reports</i> , 2017 , 7, 7931	4.9	43
32	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
31	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. <i>PLoS ONE</i> , 2017 , 12, e0182818	3.7	13
30	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017 , 37, 315-319	2.3	16
29	Second-line (SL) chemotherapy containing oxaliplatin (OXA) in metastatic pancreatic cancer (PC): Whom should we trust?. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15719-e15719	2.2	
28	Prognostic role of neutrophil-to-lymphocyte ratio (NLR) dynamics during first-line FOLFOXIRI in advanced pancreatic cancer (aPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15754-e15754	2.2	
27	Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15794-e15794	2.2	1
26	Correlation of early tumor shrinkage (ETS) and depth of response (DoR) with resectability in patients (pts) with unresectable locally advanced pancreatic cancer (LAPC) undergoing primary treatment with FOLFOXIRI.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15777-e15777	2.2	
25	Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. <i>Oncology</i> , 2016 , 91, 311-316	3.6	8
24	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. <i>Future Oncology</i> , 2016 , 12, 901-8	3.6	13

23	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1 β final results of the ALICE-2 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 280-280	2.2	10
22	Induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC): The phase II TRUST trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 673-673	2.2	
21	Radioembolization (SIRT) as a consolidation treatment in colorectal liver metastases after first line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15007-e15007	2.2	
20	Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3615-3615	2.2	
19	First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: PatientsT outcome and analysis of prognostic factors. <i>International Journal of Cancer</i> , 2016 , 139, 938-45	7.5	34
18	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016 , 91, 283-288	3.6	1
17	Comment on: Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortT <i>British Journal of Cancer</i> , 2016 , 114, e8	8.7	1
16	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2719-25	4	51
15	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 156	12.8	40
14	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 874	4.8	8
13	Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. <i>International Journal of Biological Markers</i> , 2015 , 30, e65-72	2.8	6
12	Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence. <i>Medicine (United States)</i> , 2015 , 94, e1188	1.8	16
11	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15156-e15156	2.2	
10	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014 , 110, 2165-9	8.7	56
9	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. <i>Future Oncology</i> , 2014 , 10, 285-304	3.6	11
8	Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?. <i>Oncology</i> , 2014 , 86, 191-8	3.6	16
7	Not only chemotherapy in the second-line treatment of metastatic gastric cancer. <i>Annals of Oncology</i> , 2014 , 25, 544-5	10.3	4
6	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , 2014 , 25, 2443-2444	10.3	2

5	Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6081-91	5.6	22
4	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. <i>Cancer Biology and Therapy</i> , 2013 , 14, 467-8	4.6	5
3	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013 , 24, 2062-7	10.3	74
2	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. <i>Colorectal Cancer</i> , 2012 , 1, 397-411	0.8	
1	Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter. <i>Clinical Cancer Research</i> , 2012 , 18, 4473; author reply 4474	12.9	